Bone Turnover Markers in the Diagnosis and Monitoring of Metabolic Bone Disease

Overview

Journal Clin Chem

Publisher Oxford University Press

Specialty Biochemistry

Date 2016 Dec 13

PMID 27940448

Citations 131

Authors

Matthew B Greenblatt

Joy N Tsai

Marc N Wein

Affiliations

Soon will be listed here.

Abstract

Background: Disorders of bone metabolism, most notably osteoporosis, are highly prevalent and predispose to fractures, causing high patient morbidity and mortality. Diagnosis and monitoring of bone metabolic defects can present a major challenge as these disorders are largely asymptomatic and radiographic measures of bone mass respond slowly to changes in bone physiology.

Content: Bone turnover markers (BTMs) are a series of protein or protein derivative biomarkers released during bone remodeling by osteoblasts or osteoclasts. BTMs can offer prognostic information on fracture risk that supplements radiographic measures of bone mass, but testing using BTMs has to take into account the large number of preanalytic factors and comorbid clinical conditions influencing BTM levels. BTMs respond rapidly to changes in bone physiology, therefore, they have utility in determining patient response to and compliance with therapies for osteoporosis.

Summary: BTMs are a useful adjunct for the diagnosis and therapeutic monitoring of bone metabolic disorders, but their use has to be tempered by the known limitations in their clinical utility and preanalytic variables complicating interpretation.

Citing Articles

Exon junction complexes regulate osteoclast-induced bone resorption by influencing the NFATc1 m6A distribution through the "shield effect".

Sun B, Yang J, Wang Z, Wang Z, Feng W, Li X Clin Transl Med. 2025; 15(3):e70266.

PMID: 40051055 PMC: 11885169. DOI: 10.1002/ctm2.70266.

Elevated baseline CTX levels predict enhanced therapeutic efficacy of zoledronic acid in augmenting lumbar spine bone mineral density among Chinese osteoporosis patients.

Zhang Q, Gao W, Xu X, Cui R, Su B Osteoporos Int. 2025; .

PMID: 40038109 DOI: 10.1007/s00198-025-07448-7.

Effect of GLP-1 receptor agonists on bone mineral density, bone metabolism markers, and fracture risk in type 2 diabetes: a systematic review and meta-analysis.

Tan Y, Liu S, Tang Q Acta Diabetol. 2025; .

PMID: 39985672 DOI: 10.1007/s00592-025-02468-5.

Hormonal Contraception and Bone Metabolism: Emerging Evidence from a Systematic Review and Meta-Analysis of Studies on Post-Pubertal and Reproductive-Age Women.

Tassi A, Londero A, Xholli A, Lanzolla G, Bertozzi S, Savelli L Pharmaceuticals (Basel). 2025; 18(1).

PMID: 39861124 PMC: 11768253. DOI: 10.3390/ph18010061.

Reference Intervals (RIs) of the Bone Turnover Markers (BTMs) in Children and Adolescents: A Proposal for Effective Use.

Brescia V, Lovero R, Fontana A, Zerlotin R, Colucci S, Grano M Biomedicines. 2025; 13(1).

PMID: 39857618 PMC: 11759837. DOI: 10.3390/biomedicines13010034.

References

Garnero P, Sornay-Rendu E, CHAPUY M, Delmas P . Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996; 11(3):337-49. DOI: 10.1002/jbmr.5650110307. View

Koivula M, Ruotsalainen V, Bjorkman M, Nurmenniemi S, Ikaheimo R, Savolainen K . Difference between total and intact assays for N-terminal propeptide of type I procollagen reflects degradation of pN-collagen rather than denaturation of intact propeptide. Ann Clin Biochem. 2009; 47(Pt 1):67-71. DOI: 10.1258/acb.2009.009110. View

Herrmann M, Seibel M, Seibel M . The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review. Clin Chim Acta. 2008; 393(2):57-75. DOI: 10.1016/j.cca.2008.03.020. View

Bauer D, Sklarin P, Stone K, Black D, Nevitt M, Ensrud K . Biochemical markers of bone turnover and prediction of hip bone loss in older women: the study of osteoporotic fractures. J Bone Miner Res. 1999; 14(8):1404-10. DOI: 10.1359/jbmr.1999.14.8.1404. View

Garnero P, Jouvenne P, Buchs N, Delmas P, Miossec P . Uncoupling of bone metabolism in rheumatoid arthritis patients with or without joint destruction: assessment with serum type I collagen breakdown products. Bone. 1999; 24(4):381-5. DOI: 10.1016/s8756-3282(98)00193-8. View

Leder B, Tsai J, Uihlein A, Burnett-Bowie S, Zhu Y, Foley K . Two years of Denosumab and teriparatide administration in postmenopausal women with osteoporosis (The DATA Extension Study): a randomized controlled trial. J Clin Endocrinol Metab. 2014; 99(5):1694-700. PMC: 4010689. DOI: 10.1210/jc.2013-4440. View

Hans D, Goertzen A, Krieg M, Leslie W . Bone microarchitecture assessed by TBS predicts osteoporotic fractures independent of bone density: the Manitoba study. J Bone Miner Res. 2011; 26(11):2762-9. DOI: 10.1002/jbmr.499. View

Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E . Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid. Cancer. 2008; 113(1):193-201. DOI: 10.1002/cncr.23529. View

Harvey N, Gluer C, Binkley N, McCloskey E, Brandi M, Cooper C . Trabecular bone score (TBS) as a new complementary approach for osteoporosis evaluation in clinical practice. Bone. 2015; 78:216-24. PMC: 4538791. DOI: 10.1016/j.bone.2015.05.016. View

10.

Sarkar S, Reginster J, Crans G, Diez-Perez A, Pinette K, Delmas P . Relationship between changes in biochemical markers of bone turnover and BMD to predict vertebral fracture risk. J Bone Miner Res. 2004; 19(3):394-401. DOI: 10.1359/JBMR.0301243. View

11.

Eastell R, Mallinak N, Weiss S, Ettinger M, Pettinger M, Cain D . Biological variability of serum and urinary N-telopeptides of type I collagen in postmenopausal women. J Bone Miner Res. 2000; 15(3):594-8. DOI: 10.1359/jbmr.2000.15.3.594. View

12.

Bauer D, Schwartz A, Palermo L, Cauley J, Hochberg M, Santora A . Fracture prediction after discontinuation of 4 to 5 years of alendronate therapy: the FLEX study. JAMA Intern Med. 2014; 174(7):1126-34. PMC: 4409325. DOI: 10.1001/jamainternmed.2014.1232. View

13.

Lund T, Abildgaard N, Andersen T, Delaisse J, Plesner T . Multiple myeloma: changes in serum C-terminal telopeptide of collagen type I and bone-specific alkaline phosphatase can be used in daily practice to detect imminent osteolysis. Eur J Haematol. 2010; 84(5):412-20. PMC: 2871171. DOI: 10.1111/j.1600-0609.2010.01417.x. View

14.

Cosman F, Eriksen E, Recknor C, Miller P, Guanabens N, Kasperk C . Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. J Bone Miner Res. 2010; 26(3):503-11. DOI: 10.1002/jbmr.238. View

15.

Igarashi Y, Lee M, Matsuzaki S . Acid phosphatases as markers of bone metabolism. J Chromatogr B Analyt Technol Biomed Life Sci. 2002; 781(1-2):345-58. DOI: 10.1016/s1570-0232(02)00431-2. View

16.

Whyte M . Paget's disease of bone and genetic disorders of RANKL/OPG/RANK/NF-kappaB signaling. Ann N Y Acad Sci. 2006; 1068:143-64. DOI: 10.1196/annals.1346.016. View

17.

Klappacher G, Franzen P, HaaB D, Mehrabi M, Binder M, Plesch K . Measuring extracellular matrix turnover in the serum of patients with idiopathic or ischemic dilated cardiomyopathy and impact on diagnosis and prognosis. Am J Cardiol. 1995; 75(14):913-8. DOI: 10.1016/s0002-9149(99)80686-9. View

18.

Midtby M, Magnus J, Joakimsen R . The Tromsø Study: a population-based study on the variation in bone formation markers with age, gender, anthropometry and season in both men and women. Osteoporos Int. 2001; 12(10):835-43. DOI: 10.1007/s001980170034. View

19.

Garnero P, Ferreras M, Karsdal M, Nicamhlaoibh R, Risteli J, Borel O . The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation. J Bone Miner Res. 2003; 18(5):859-67. DOI: 10.1359/jbmr.2003.18.5.859. View

20.

Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G . An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem Biophys Res Commun. 2010; 397(4):691-6. PMC: 2913292. DOI: 10.1016/j.bbrc.2010.06.008. View